[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100513700":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":33,"locations":38,"responsibleParty":55,"collaborators":25,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":25,"eligibilityCriteria":63,"healthyVolunteers":59,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":25,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":78,"overallStatus":40,"whyStopped":25,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Mackay Memorial Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intradetrusor onabotulinumtoxinA injection","ACTIVE_COMPARATOR","The toxin produced by Clostridium botulinum binds to the nerves endings and inhibits the muscular contractions, help to treat overactivity of the bladder muscles.",[13],"Procedure: Intradetrusor Botox® (onabotulinumtoxinA) injection",{"label":15,"type":16,"description":17,"interventionNames":18},"Combination pharmacotherapy","EXPERIMENTAL","Combine Mirabegron and Solifenacin.",[19],"Drug: Combine Mirabegron and Solifenacin.",[21,26],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"PROCEDURE","Intradetrusor Botox® (onabotulinumtoxinA) injection",[9],null,{"type":27,"name":17,"description":15,"armGroupLabels":28,"otherNames":25},"DRUG",[15],[30],{"name":31,"affiliation":5,"role":32},"Hui-Hsuan Lau, MD","PRINCIPAL_INVESTIGATOR",[34],{"name":31,"role":35,"phone":36,"phoneExt":25,"email":37},"CONTACT","+886-2-25433535","huihsuan1220@gmail.com",[39],{"facility":5,"status":40,"city":41,"state":25,"zip":25,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"RECRUITING","Taipei","Taiwan","TW",{"type":45,"coordinates":46},"Point",[47,48],121.52639,25.05306,{"lat":48,"lon":47},[51],{"name":52,"role":35,"phone":53,"phoneExt":25,"email":54},"Jiun Chyi Hwang, MD","+886-2-2543-3535","jiun1989@gmail.com",{"type":32,"investigatorFullName":31,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Head of urogynecology, Associate Professor","100513700","phase-4-evaluation-the-efficacy-between-botox-injection-and-combination-pharmacotherapy-in-patients-with-detrusor-overactivity-100513700",false,"NCT05968885","Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity","Evaluation of the Efficacy and Urodynamic Outcomes Between Intradetrusor onabotulinumtoxinA Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity","Inclusion Criteria:\n\n* Patients with detrusor overactivity which defined as a urodynamic observation characterized by involuntary detrusor contractions during the filling phase. Those who were refractory to monotherapy with either anti-muscarinics or β3-adrenoceptor agonists were enrolled for prospective study\n\nExclusion Criteria:\n\n* Postvoid urine retention before treatment","FEMALE","20 Years","90 Years",{"count":68,"type":69},300,"ESTIMATED","INTERVENTIONAL",[72],"PHASE4","To investigates the effects of botulinum toxin type A bladder injection compared to combined pharmacotherapy with Mirabegron and Solifenacin.",[75,76,77],"Urinary Bladder, Overactive","Urodynamics","Effect of Drug",[79,80,81,82,83],"Detrusor overactivity","Urodynamic study","Combined pharmacotherapy","Botulinum Toxins","Effectiveness","2025-05-06",{"date":86,"type":87},"2025-05-09","ACTUAL",{"date":89,"type":87},"2021-10-01",{"date":91,"type":69},"2026-12-31",{"name":5,"class":6},1]